Cassava Sciences Inc SAVA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SAVA is a good fit for your portfolio.
News
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava
-
ROSEN, A LONGSTANDING LAW FIRM, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action - SAVA
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAVA
-
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, NYCB, Amylyx, and InMode and Encourages Investors to Contact the Firm
-
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important April 2 Deadline in Securities Class Action – SAVA
-
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA
Trading Information
- Previous Close Price
- $20.41
- Day Range
- $20.20–20.54
- 52-Week Range
- $12.33–32.05
- Bid/Ask
- $20.33 / $20.44
- Market Cap
- $883.51 Mil
- Volume/Avg
- 48,783 / 715,558
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx, and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer’s disease dementia.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 29
- Website
- https://www.cassavasciences.com
Comparables
Valuation
Metric
|
SAVA
|
AVXL
|
CERE
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.27 | 3.06 | 11.41 |
Price/Sales | — | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
SAVA
AVXL
CERE
Financial Strength
Metric
|
SAVA
|
AVXL
|
CERE
|
---|---|---|---|
Quick Ratio | 8.60 | 11.79 | 10.81 |
Current Ratio | 9.13 | 11.85 | 10.92 |
Interest Coverage | — | — | −44.07 |
Quick Ratio
SAVA
AVXL
CERE
Profitability
Metric
|
SAVA
|
AVXL
|
CERE
|
---|---|---|---|
Return on Assets (Normalized) | −47.53% | −21.26% | −38.51% |
Return on Equity (Normalized) | −51.26% | −23.17% | −84.00% |
Return on Invested Capital (Normalized) | −55.59% | −27.24% | −49.36% |
Return on Assets
SAVA
AVXL
CERE
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Sbffyhky | Hjhpw | $571.0 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Tfdpzysc | Xygdmr | $107.8 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qqbwxvqsq | Mxgpsm | $106.1 Bil | |
MRNA
| Moderna Inc | Frlbrflq | Wrn | $42.3 Bil | |
ARGX
| argenx SE ADR | Jzwrqkfjz | Sddwt | $23.7 Bil | |
BNTX
| BioNTech SE ADR | Slbfnxmg | Mbtdb | $22.1 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Rvqjxyx | Fpfskqg | $19.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Jhmhlfyx | Thxwbwl | $16.7 Bil | |
RPRX
| Royalty Pharma PLC Class A | Wqtcfmgrn | Gzmzyd | $13.6 Bil | |
INCY
| Incyte Corp | Ltzqrkz | Czsvyg | $12.8 Bil |